Delving into the Latest Updates on L&L Biopharma Co., Ltd. with Synapse

Overview

Basic Info

Introduction

L&L Biopharma Co., Ltd. is a company engaged in the field of biopharmaceuticals, focusing on the preclinical research and development of new drugs in the direction of tumor immunotherapy, specializing in the innovation of monoclonal antibody new drugs, CAR-T (Chimeric Antigen Receptor T Cell) technology, and the development of combined treatment products.

Tags

Neoplasms

Digestive System Disorders

Urogenital Diseases

Bispecific antibody

Trispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Bispecific antibody	4
Trispecific antibody	2

Top 5 Target	Count

PD-1 x TIM3	1
CD8 x CLDN18.2	1

This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330）versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.

Start Date01 Oct 2025

Sponsor / Collaborator

L&L Biopharma Co., Ltd.

CTR20222918

/ TerminatedPhase 1

评价 LB4330 在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征及免疫原性的剂量递增及剂量扩展的Ⅰ期临床试验

[Translation] Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of LB4330 in patients with advanced malignant solid tumors

主要目的：评价 LB4330 在晚期恶性实体瘤患者中的安全性和耐受性，并探索 LB4330 的最大耐受剂量（MTD），确定Ⅱ期临床试验推荐剂量（RP2D）。次要目的： 1）评价 LB4330 在晚期实体瘤患者中的药代动力学（PK）和药效动力学（PD）特征。 2）评价 LB4330 在晚期实体瘤患者中的免疫原性。 3）初步评价 LB4330 在晚期实体瘤患者中的抗肿瘤疗效。 4）初步评价 LB4330 治疗晚期恶性肿瘤患者的疗效相关的生物标志物，为Ⅱ期临床试验的治疗人群选择提供依据。

[Translation]

Primary objectives: To evaluate the safety and tolerability of LB4330 in patients with advanced malignant solid tumors, explore the maximum tolerated dose (MTD) of LB4330, and determine the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of LB4330 in patients with advanced solid tumors. 2) To evaluate the immunogenicity of LB4330 in patients with advanced solid tumors. 3) To preliminarily evaluate the anti-tumor efficacy of LB4330 in patients with advanced solid tumors. 4) To preliminarily evaluate the biomarkers related to the efficacy of LB4330 in the treatment of patients with advanced malignant tumors, and provide a basis for the selection of treatment populations for Phase II clinical trials.

Start Date30 Nov 2022

Sponsor / Collaborator

L&L Biopharma Co., Ltd.

100 Clinical Results associated with L&L Biopharma Co., Ltd.

Login to view more data

0 Patents (Medical) associated with L&L Biopharma Co., Ltd.

Login to view more data

100 Deals associated with L&L Biopharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with L&L Biopharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

2

Phase 3

Other

9

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant PD-1/TIM3 bispecific antibody(L&L vision biopharmaceuticals) ( PD-1 x TIM3 )	Non-Small Cell Lung Cancer More	Phase 1
LB-4330 ( CD8 x CLDN18.2 )	Stomach Cancer More	Phase 1
Bis98	Neoplasms More	Preclinical
L016	Neoplasms More	Preclinical
LNL021	Neoplasms More	Preclinical